ANIVIO

house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; biologics; biosimilars; pharmaceuticals; biologic, biosimilar, and pharmaceutical preparations; biologic, biosimilar, and pharmaceutical products; anti-TNF alpha antibodies; monoclonal antibodies; anti-inflammatories; anti-inflammatory biologic, biosimilar, and pharmaceutical preparations; biologic, biosimilar, and pharmaceutical preparations for the treatment of lung diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of inflammatory disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of pulmonary sarcoidosis; biologic, biosimilar, and pharmaceutical preparations for the treatment of sarcoidosis; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent granulomas; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent fibrosis; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of inflammatory diseases and disorders; self-replicating mRNA; pharmaceutical preparations containing self-replicating mRNA; pharmaceutical preparations containing self-replicating mRNA for the treatment of lung diseases and disorders, inflammatory disorders, pulmonary sarcoidosis, sarcoidosis; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent granulomas; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent fibrosis

research and development of biologics, biosimilars, pharmaceuticals, and self-replicating mRNA; providing information in the field of scientific and medical research related to biologics, biosimilars, pharmaceuticals, and self-replicating mRNA

providing medical information; providing health information